ES2459496T3 - Diaza-espiro[5.5]undecanos como antagonistas del receptor de orexina - Google Patents

Diaza-espiro[5.5]undecanos como antagonistas del receptor de orexina Download PDF

Info

Publication number
ES2459496T3
ES2459496T3 ES10805703.5T ES10805703T ES2459496T3 ES 2459496 T3 ES2459496 T3 ES 2459496T3 ES 10805703 T ES10805703 T ES 10805703T ES 2459496 T3 ES2459496 T3 ES 2459496T3
Authority
ES
Spain
Prior art keywords
undecan
diazaspiro
methyl
quinoxalin
ring system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10805703.5T
Other languages
English (en)
Spanish (es)
Inventor
Sangamesh Badiger
Dirk Behnke
Claudia Betschart
Vinod Chaudhari
Simona Cotesta
Jürgen Hans-Hermann HINRICHS
Silvio Ofner
Chetan Pandit
Jürgen Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2459496T3 publication Critical patent/ES2459496T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES10805703.5T 2009-12-21 2010-12-20 Diaza-espiro[5.5]undecanos como antagonistas del receptor de orexina Active ES2459496T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
INDE26632009 2009-12-21
IN2663DE2009 2009-12-21
PCT/EP2010/070263 WO2011076747A1 (en) 2009-12-21 2010-12-20 Diaza-spiro[5.5]undecanes as orexin receptor antagonists

Publications (1)

Publication Number Publication Date
ES2459496T3 true ES2459496T3 (es) 2014-05-09

Family

ID=43640117

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10805703.5T Active ES2459496T3 (es) 2009-12-21 2010-12-20 Diaza-espiro[5.5]undecanos como antagonistas del receptor de orexina

Country Status (9)

Country Link
US (1) US8530648B2 (enExample)
EP (1) EP2516439B1 (enExample)
JP (1) JP2013515033A (enExample)
CN (1) CN102762567A (enExample)
AR (1) AR079553A1 (enExample)
ES (1) ES2459496T3 (enExample)
TW (1) TW201132642A (enExample)
UY (1) UY33125A (enExample)
WO (1) WO2011076747A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120101110A1 (en) * 2010-10-26 2012-04-26 Sangamesh Badiger Diaza-spiro[5.5]undecanes
US20120165331A1 (en) * 2010-12-22 2012-06-28 Sangamesh Badiger Di/tri-aza-spiro-C9-C11alkanes
NZ628491A (en) 2012-02-07 2016-06-24 Eolas Therapeutics Inc Substituted prolines / piperidines as orexin receptor antagonists
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
ITMI20120424A1 (it) 2012-03-19 2013-09-20 Rottapharm Spa Composti chimici
EP3099667B1 (en) * 2014-01-27 2017-11-01 Allergan, Inc. Antagonists acting at multiple prostaglandin receptors for the treatment of inflammation
JP2017100951A (ja) * 2014-04-04 2017-06-08 大正製薬株式会社 オキサゾリジノン及びオキサジナノン誘導体
JP6663909B2 (ja) 2014-08-13 2020-03-13 エオラス セラピューティクス， インコーポレイテッド オレキシンレセプターモジュレーターとしてのジフルオロピロリジン
US10196383B2 (en) 2015-07-17 2019-02-05 Sunshine Lake Pharma Co., Ltd. Substituted quinazoline compounds and preparation and uses thereof
SI3414241T1 (sl) 2016-02-12 2022-10-28 Astrazeneca Ab Halo-substituitani piperidini kot modulatorji receptorja oreksina
WO2018026798A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda modulators and methods of using same
ES2972533T3 (es) 2016-08-01 2024-06-13 Tenacia Biotechnology Hong Kong Co Ltd Moduladores del receptor de NMDA a base de espirolactama, y sus usos
EA201990424A1 (ru) 2016-08-01 2019-08-30 Аптиникс Инк. Спиролактамовые модуляторы nmda-рецептора и их применение
CN106831774B (zh) * 2017-02-07 2019-02-01 上海合全药业股份有限公司 一种(6s，7s)-9-叔丁氧羰基-7-(三氟甲基)-2，9-二氮杂螺[5.5]十一烷的合成方法
KR102761196B1 (ko) 2018-01-31 2025-02-03 테나시아 바이오테크놀로지 (홍콩) 코., 리미티드 스피로-락탐 nmda 수용체 조정제 및 그의 용도
AU2020216214A1 (en) * 2019-01-28 2021-07-08 Suntory Holdings Limited Composition for competitive inhibition of orexin receptors
KR20230051227A (ko) 2020-08-14 2023-04-17 노파르티스 아게 헤테로아릴 치환된 스피로피페리디닐 유도체 및 이의 제약 용도
MX2023012971A (es) * 2021-05-03 2024-01-16 Jazz Pharmaceuticals Ireland Ltd Agonistas del receptor de orexina y sus usos.
WO2023081094A1 (en) * 2021-11-04 2023-05-11 University Of Washington Novel spirocyclic compounds as klhdc2 ligands

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
JP4496722B2 (ja) * 2002-06-28 2010-07-07 萬有製薬株式会社 新規ベンズイミダゾール誘導体
US7105526B2 (en) * 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US20090176789A1 (en) * 2005-08-26 2009-07-09 Breslin Michael J Diazaspirodecane orexin receptor antagonists
PL1961744T3 (pl) * 2005-11-18 2013-09-30 Ono Pharmaceutical Co Związek zawierający grupę zasadową oraz jego zastosowanie

Also Published As

Publication number Publication date
UY33125A (es) 2011-07-29
EP2516439B1 (en) 2014-01-22
JP2013515033A (ja) 2013-05-02
US20120264748A1 (en) 2012-10-18
CN102762567A (zh) 2012-10-31
TW201132642A (en) 2011-10-01
WO2011076747A1 (en) 2011-06-30
AR079553A1 (es) 2012-02-01
US8530648B2 (en) 2013-09-10
EP2516439A1 (en) 2012-10-31

Similar Documents

Publication Publication Date Title
ES2459496T3 (es) Diaza-espiro[5.5]undecanos como antagonistas del receptor de orexina
US10829501B2 (en) Spiroheptane salicylamides and related compounds as inhibitors of ROCK
ES2460915T3 (es) Piridinas fusionadas con heteroarilo disustituido
US11952381B2 (en) Cardiac sarcomere inhibitors
ES2774945T3 (es) 2,4-dihidroxi-nicotinamidas como agonistas de APJ
EP3134408B1 (en) FACTOR XIa INHIBITORS
AU2013312931B2 (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
US20120165331A1 (en) Di/tri-aza-spiro-C9-C11alkanes
KR20210013145A (ko) 키나아제 억제제로서 헤테로시클릭 화합물, 헤테로시클릭 화합물을 포함하는 조성물 및 그 사용 방법
AU2016372048A1 (en) Heteroarylhydroxypyrimidinones as agonists of the APJ receptor
KR20160055190A (ko) 트립토판 하이드록실레이스 억제제로서 스파이로사이클릭 화합물
AU2004231087A1 (en) Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors
CA2837312A1 (en) Metabotropic glutamate receptor 5 allosteric modulators and methods of use thereof
CA3096732A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
WO2014146493A1 (en) Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors
JP2021521142A (ja) Ｃｒｈｒ２拮抗薬としての縮合環状尿素誘導体
WO2024026484A2 (en) Cdk2 inhibitors and methods of using the same
US20120101110A1 (en) Diaza-spiro[5.5]undecanes
KR20230015404A (ko) 무스카린성 아세틸콜린 수용체 m5의 경쟁적 억제제 및 비경쟁적 억제제